

RECEIVED

FEB 24 2003

PATENT

ATTORNEY DOCKET NO.: 051294-5941
TECH CENTER 1800/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In PATENT APPLICATION of:

KETTLE et al.

Appln. No.: 09/889,599

Filed: October 19, 2001

FOR: INDOLE DERIVATIVES AND THEIR USE
AS MCP-1 ANTAGONISTS

Group Art Unit: 1614

Examiner: Robinson, Binta

Commissioner of Patents
Washington, D.C. 20231

Date: February 24, 2003

Sir:

INFORMATION DISCLOSURE STATEMENT

Citation of Related U.S. Patent Applications

The Examiner's attention is directed to the following related co-pending U.S. patent applications:

Examiner's Initials	Inventor	U.S. Serial No.	U.S. Filing Date	PCT Publication No.	PCT Publication Date
	Faull et al.	09/889,494	07/18/01	WO 00/46198	10 Aug. 00
	Faull et al.	09/889,493	07/02/01	WO 00/46197	10 Aug. 00
	Faull et al.	09/889,516	10/02/01	WO 00/46199	10 Aug. 00
	Faull et al.	09/889,515	07/18/01	WO 00/46195	10 Aug. 00
	Faull et al.	09/485,061 [US 6,441,004]	02/03/2000	WO 99/07351*	18 Feb. 99
	Faull et al.	10/194,969	07/15/2002	WO 99/07351*	18 Feb. 99
	Faull et al.	09/485,107 [US 6,288,103]	02/03/2000	WO 99/07678*	18 Feb. 99
	Faull et al.	09/626,241 [US 6,291,507]	07/26/2000	WO 99/40913	19 Aug. 99
	Barker et al.	09/626,378 [US 6,479,527]	07/26/2000	WO 99/40914	19 Aug. 99
				WO 01/51467	19 July 01
	Faull et al.	10/169,717	07/09/02	WO 01/51466	19 July 01

02/25/2003 YPOLITE1 00000162 500310 09889599

02 FC:1806 180.00 CH

A copy of the specification and claims for each application, either in the form of a U.S. patent issued on that application or the published PCT application from which such application was filed, has previously been provided or is being filed herewith. Specifically, the **bolded** U.S. Patent or PCT application corresponding to each application is submitted herewith, except that a copy of the bolded published PCT applications followed by an asterisk (*) on the above list was already submitted to the Patent and Trademark Office in a parent application, and listed on the form PTO-1449 filed with this application on July 18, 2001. The remaining bolded documents submitted herewith are listed on the accompanying form PTO-1449. The undersigned understands that the text of each related application is essentially the same as the corresponding published PCT and should be the same as the text of the listed U.S. patent issuing thereon.

PLEASE DO NOT PRINT the above information on the patent resulting from the subject application.

Consideration of each listed application is earnestly solicited since unpublished patent applications are contemplated as IDS material; see the exception in Rule 98(a)(2)(iii) and note the penultimate sentence of MPEP 609.

Further, in keeping with MPEP 609, Subsec. C(2), 2nd para., line 10 to end of the paragraph (especially note lines 18-25) PLEASE RETURN A COPY OF THIS LETTER with the Examiner's initials adjacent each above listing so that applicant will know that each listed application has been considered as required by PTO policy.

Citation of Documents

Attached is a Form PTO-1449 listing the enclosed documents.

This Information Disclosure Statement is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to fully comply.


Please charge the Rule 17(p) official fee required by Rule 97(c) to our Deposit Account No. 50-0310 under Order No. 056291-5041.

Consideration of the foregoing and enclosures plus the return of a copy of the herewith filed Form PTO-1449 with the Examiner's initials in the left column per MPEP 609 along with an early action on the merits of this application are earnestly solicited.

Except for issue fees payable under 37 C.F.R. §1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** -in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully Submitted,
Morgan Lewis & Bockius LLP

By:


Donald J. Bird
Registration No. 25,323
Tel. No.: (202) 739-5320
Fax No.: (202) 739-3001

Date: February 24, 2003
Morgan Lewis & Bockius LLP
Customer No. **009629**
1111 Pennsylvania Avenue, N.W.
Washington, D.C. 20004
Tel. No.: 202-739-3000
DJB:mk